United Therapeutics (UTHR) delivered one of the most dramatic single-day gains in recent memory this week. After announcing positive Phase 3 trial results for its Tyvaso drug – a new formulation in idiopathic pulmonary fibrosis (IPF) – the stock surged overnight.
For Devotion Capital, this was especially significant: UTHR is one of our largest portfolio holdings. With a cost basis just over $300 per share, we went from roughly breakeven on the position to a 40% gain literally overnight. True to the adage “sell on the news,” we trimmed the position Tuesday, September 2nd between $427 and $435 per share.
If “idiopathic pulmonary fibrosis” sounds unfamiliar, you’re not alone. In plain terms: a UTHR drug just gained a powerful new use, which means it’s going to be prescribed much more widely.
What Is IPF?
Idiopathic Pulmonary Fibrosis (IPF) is a progressive scarring of the lungs that makes breathing harder over time.
Tyvaso was already approved for two pulmonary conditions (PAH and PH-ILD).
The new Phase 3 results showed Tyvaso significantly slowed IPF’s progression.
Why it matters: IPF affects a much larger patient population, meaning Tyvaso’s market opportunity just grew significantly.
We did not invest in UTHR on the basis of unproven drug development. We bought it because of what it already is: a company with a fortress balance sheet and incredible free cash flow generation. The possibilities in the firm’s drug pipeline were simply a bonus. In this case, that optionality paid off – a 40% gain essentially overnight.
Culture vs. Finances
United Therapeutics’ culture has a distinctly unconventional feel. Management often refers to employees as “Unitherians”. But while the company can sound New Age, the finances are anything but. UTHR’s results are grounded in old-fashioned discipline:
Why We Owned It Before the News
Balance Sheet Strength
UTHR carries nearly $5 billion in net cash—about $110 per share—and no debt. In a sector often burdened with leverage and dilution, this is extraordinary. To put this in context, United Therapeutics was valued at $13.5 billion (= $300 a share x 45 million total shares). The company’s cash balance represented more than 1/3 of the total market value of the company. And again, the company is essentially debt free.
Cash Flow Profile
The company also generates more than $1 billion in free cash flow annually. Free cash flow is essentially a company’s “cash profit” — the money left over after paying all expenses and necessary investments, which can be used to strengthen the balance sheet, reinvest in growth, or return to shareholders.
Capital Allocation Reality
Unlike many biotechs, UTHR funds its research internally. While share count has crept upward over time due to stock-based compensation, the company has not been reckless with shareholder dilution.
Downside Protection
Tyvaso, Remodulin, and Adcirca royalties form a durable cash flow base. Even with no pipeline success, the intrinsic value was clear.
The Bonus Catalyst – Optionality
In investing, “optionality” means having exposure to upside opportunities. In the case of UTHR, our valuation work reinforced that we got these options without paying for them.
The recent positive Phase 3 results in IPF were not central to our thesis – far from it. Yet as value investors, we recognized that UTHR’s pipeline created real option value that the market was not reflecting in the stock price making the purchase even more compelling. In short, we were buying robust cash flows and a fortress balance sheet, while getting pipeline upside essentially for free. With that optionality seemingly paying off, thanks to a new use for Tyvaso, it created immediate value and propelled the stock to a new valuation range.
Strategic Context: A Takeout Candidate?
We have long believed UTHR would be a natural acquisition target for big pharma. Consider:
Digestible Size: Even at its new market value of ~$19–20 billion market cap, UTHR is small enough to be acquired, yet large enough to move the needle for a larger pharmaceutical company, like Pfizer or Bristol Myers.
Under-Leveraged: With ~$5 billion in net cash, an acquirer could use UTHR’s balance sheet to help fund the purchase.
Pipeline Plug-In: Tyvaso’s expansion into IPF, combined with rare-disease programs and organ-transplant initiatives, fills critical gaps in large pharma pipelines.
Big Pharma Dynamics: With looming patent cliffs and cash-rich balance sheets, the majors are under pressure to buy growth. UTHR would fill that prescription.
Lessons for Devotion Capital Clients
- We buy assets, not hope. UTHR was already attractive on cash and cash flow alone.
- Optionality is a free bonus. If it pays off, the upside is considerable.
- Capital market reality matters. With large pharmaceutical companies under pressure to grow, UTHR is a potential acquisition target but it is also a value if it remains independent.
Conclusion:
United Therapeutics exemplifies Devotion Capital’s investment philosophy. By focusing on durable balance sheets and real cash generation purchased at a reasonable price, we create portfolios with downside protection and upside.
To all our clients:
Thank you for the trust you have placed in us. It is our privilege and pleasure to invest on your behalf.
Referrals are the lifeblood of our business.
If you know friends or family who might appreciate our approach—or who may be interested in our investment management services—we would be honored if you shared Devotion Capital with them.
To those not yet clients:
We invite you to consider Devotion Capital. We are value investors—independent, disciplined, and long-term in focus—always investing alongside our clients with interests fully aligned.
Henry W. Schacht, CFA
Devotion Capital Management
